A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenoid cystic carcinoma
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO 2019).
- 23 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2017 Status changed from not yet recruiting to recruiting.